Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease

Arthritis and Rheumatism
Anne Grete SembIngar Holme

Abstract

To examine the effect of intensive lipid-lowering therapy on a composite cardiovascular outcome (cardiovascular disease [CVD]), consisting of mortality and morbidity end points, in patients with inflammatory joint disease (rheumatoid arthritis [RA], ankylosing spondylitis [AS], or psoriatic arthritis [PsA]) by post hoc analysis of 2 prospective trials of statins with a secondary end point of CVD outcome (the Treating to New Targets [TNT] and Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] studies). Of the 18,889 patients participating in the 2 trials, 199 had RA, 46 had AS, and 35 had PsA. Lipid-lowering therapy consisted of an intensive regimen of atorvastatin 80 mg or a conventional/low-dose regimen of atorvastatin 10 mg or simvastatin 20-40 mg. The median duration of followup was nearly 5 years. Changes in lipid levels were examined by analyses of covariance. The effect on CVD was examined by Cox regression analyses, and heterogeneity tests were performed. Patients with RA and those with AS had lower baseline cholesterol levels than patients without inflammatory joint disease (least squares mean ± SEM 180.7 ± 2.3 mg/dl and 176.5 ± 4.7 mg/dl, respectively, versus 185.6 ± 0.2 mg/dl; P = 0.03 and P ...Continue Reading

References

Dec 1, 1992·Seminars in Arthritis and Rheumatism·M B LazarevicW I Swedler
Nov 1, 1994·Annals of Internal Medicine·B KinosianG Garland
Jan 14, 1999·The New England Journal of Medicine·R Ross
Jun 22, 1999·The New England Journal of Medicine·G D Sloop
Mar 13, 2001·Blood Purification·C A Dinarello, B J Pomerantz
Jul 19, 2002·Arthritis and Rheumatism·Yong-Beom ParkSoo-Kon Lee
Mar 12, 2003·Circulation·Daniel H SolomonGary C Curhan
Dec 21, 2004·Seminars in Arthritis and Rheumatism·Mike J PetersMichael T Nurmohamed
Feb 15, 2005·Annals of the Rheumatic Diseases·D J VealeO FitzGerald
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Oct 13, 2005·Annals of the Rheumatic Diseases·J C van DenderenM T Nurmohamed
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Jun 17, 2006·Nature Reviews. Immunology·Göran K Hansson, Peter Libby
Nov 30, 2006·Archives of Internal Medicine·Paaladinesh ThavendiranathanNiteesh K Choudhry
Sep 12, 2007·Experimental Dermatology·Robert SabatKerstin Wolk
Dec 21, 2007·Clinical Reviews in Allergy & Immunology·Brian J NickoloffFrank O Nestle
Nov 13, 2008·BMJ : British Medical Journal·Jorie VersmissenEric J G Sijbrands
May 13, 2009·Annals of the Rheumatic Diseases·Misato HashizumeMasahiko Mihara
Dec 4, 2009·The Journal of Rheumatology·Mike J L PetersMichael T Nurmohamed
May 18, 2010·The Journal of Rheumatology·Anne-Marie TobinBrian Kirby
Jul 22, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Sylvain MathieuMartin Soubrier
Oct 5, 2010·Arthritis Care & Research·Sylvain MathieuMartin Soubrier
Feb 25, 2011·Annals of the Rheumatic Diseases·Cynthia S Crowson, Sherine E Gabriel

❮ Previous
Next ❯

Citations

May 8, 2013·Zeitschrift für Rheumatologie·H Pieringer, U C Hoppe
Aug 13, 2013·Annals of the Rheumatic Diseases·Patrick H Dessein, Anne G Semb
Jun 8, 2014·Annals of the Rheumatic Diseases·Miguel A González-Gay, Carlos González-Juanatey
Feb 20, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nicola Ferri, Alberto Corsini
Aug 6, 2014·Nature Reviews. Nephrology·Silvio Garattini, Norberto Perico
Jun 27, 2014·International Journal of Molecular Sciences·Curtis M Steyers, Francis J Miller
Dec 19, 2013·Expert Review of Clinical Immunology·Xavier GuillotDaniel Wendling
Aug 22, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jesper LindhardsenOle Ahlehoff
Jun 17, 2014·International Journal of Rheumatic Diseases·Kathrin DanningerHerwig Pieringer
Jun 29, 2015·Autoimmunity Reviews·I HollanP L Meroni
Apr 11, 2015·BioMed Research International·Patrick H DesseinCalin D Popa
Apr 1, 2015·Nature Reviews. Rheumatology·Sarah Skeoch, Ian N Bruce
Jan 6, 2015·Seminars in Arthritis and Rheumatism·Erardo Meriño-Ibarra
Feb 5, 2015·Seminars in Arthritis and Rheumatism·María A Martín-MartínezMiguel A González-Gay
May 11, 2015·Clinical Rheumatology·Lianne S Gensler
Dec 3, 2014·Reumatología clinica·Erardo Meriño-Ibarra, Concepción Delgado-Beltrán
Dec 25, 2012·Annals of the Rheumatic Diseases·Silvia RollefstadAnne Grete P Semb
Jul 1, 2016·Nature Reviews. Rheumatology·Anne Grete Semb, Silvia Rollefstad
Aug 8, 2015·Annals of the Rheumatic Diseases·Sara R SchoenfeldHyon K Choi
Aug 21, 2016·International Journal of Cardiology·A G SembS Rollefstad
Aug 2, 2013·Therapeutic Advances in Musculoskeletal Disease·Inge A M van den OeverMichael T Nurmohamed
Mar 24, 2017·PloS One·Cynthia S CrowsonUNKNOWN A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA)
Feb 24, 2018·Frontiers in Medicine·Stergios SoulaidopoulosGeorge D Kitas
Oct 11, 2016·Therapeutic Advances in Musculoskeletal Disease·Anne TournadreMartin Soubrier
Oct 19, 2017·Current Atherosclerosis Reports·Michael Garshick, James A Underberg
Jul 13, 2017·Annals of the Rheumatic Diseases·Amar OzaHyon K Choi
Nov 3, 2016·The Journal of Rheumatology·Eric L Matteson, Rekha Mankad
Nov 3, 2016·The Journal of Rheumatology·Maaike Heslinga, Michael T Nurmohamed
Nov 21, 2018·International Reviews of Immunology·Antonis A ManolisAntonis S Manolis
Jun 30, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Maria Garcia-GilMaría Grau

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.